Latest Conference Articles

December 8th 2024, 2:31am

ASH Annual Meeting and Exposition

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.

December 8th 2024, 1:43am

ASH Annual Meeting and Exposition

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

December 7th 2024, 6:52pm

ASH Annual Meeting and Exposition

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

December 7th 2024, 3:00pm

ASH Annual Meeting and Exposition

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

December 7th 2024, 3:00pm

ASH Annual Meeting and Exposition

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

December 6th 2024, 8:53pm

ASH Annual Meeting and Exposition

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

November 25th 2024, 9:34pm

Society for Neuro-Oncology Annual Meeting

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

November 25th 2024, 6:30pm

Society for Neuro-Oncology Annual Meeting

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

November 25th 2024, 1:11pm

Society for Neuro-Oncology Annual Meeting

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

November 25th 2024, 12:58pm

Society for Neuro-Oncology Annual Meeting

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

November 24th 2024, 5:55pm

Society for Neuro-Oncology Annual Meeting

Larotrectinib produced rapid and durable responses and a high DCR in pediatric patients with TRK fusion–positive primary central nervous system tumors.

November 24th 2024, 12:00am

Society for Neuro-Oncology Annual Meeting

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

November 23rd 2024, 10:49pm

Society for Neuro-Oncology Annual Meeting

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

November 23rd 2024, 7:37pm

Society for Neuro-Oncology Annual Meeting

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

November 23rd 2024, 5:55pm

Society for Neuro-Oncology Annual Meeting

Tovorafenib generated durable drug holiday responses in pediatric patients with BRAF-altered relapsed/refractory low-grade glioma.

November 23rd 2024, 5:29pm

Society for Neuro-Oncology Annual Meeting

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

November 23rd 2024, 12:12am

Society for Neuro-Oncology Annual Meeting

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

November 22nd 2024, 11:54pm

Society for Neuro-Oncology Annual Meeting

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

November 22nd 2024, 9:25pm

Society for Neuro-Oncology Annual Meeting

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

November 22nd 2024, 9:25pm

PER® Chemotherapy Foundation Symposium (CFS)

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.